IL146410A0 - Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2] oct-3-yl)-(1so-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists - Google Patents
Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2] oct-3-yl)-(1so-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonistsInfo
- Publication number
- IL146410A0 IL146410A0 IL14641000A IL14641000A IL146410A0 IL 146410 A0 IL146410 A0 IL 146410A0 IL 14641000 A IL14641000 A IL 14641000A IL 14641000 A IL14641000 A IL 14641000A IL 146410 A0 IL146410 A0 IL 146410A0
- Authority
- IL
- Israel
- Prior art keywords
- ammoniumchloride
- benzhydryl
- azabicyclo
- polymorphs
- methoxybenzyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14023399P | 1999-06-22 | 1999-06-22 | |
| PCT/IB2000/000756 WO2000078759A1 (en) | 1999-06-22 | 2000-06-06 | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL146410A0 true IL146410A0 (en) | 2002-07-25 |
Family
ID=22490317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14641000A IL146410A0 (en) | 1999-06-22 | 2000-06-06 | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2] oct-3-yl)-(1so-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6262067B1 (tr) |
| EP (1) | EP1187834A1 (tr) |
| JP (1) | JP2003502425A (tr) |
| KR (1) | KR20020030280A (tr) |
| CN (1) | CN1390216A (tr) |
| AP (1) | AP2001002367A0 (tr) |
| AR (1) | AR024411A1 (tr) |
| AU (1) | AU767336B2 (tr) |
| BG (1) | BG106205A (tr) |
| BR (1) | BR0011835A (tr) |
| CA (1) | CA2375265A1 (tr) |
| CO (1) | CO5190663A1 (tr) |
| CZ (1) | CZ20014458A3 (tr) |
| DZ (1) | DZ3055A1 (tr) |
| EA (1) | EA004264B1 (tr) |
| EC (1) | ECSP003538A (tr) |
| EE (1) | EE200100698A (tr) |
| HR (1) | HRP20010920A2 (tr) |
| HU (1) | HUP0201694A3 (tr) |
| IL (1) | IL146410A0 (tr) |
| IS (1) | IS6161A (tr) |
| MA (1) | MA26744A1 (tr) |
| MX (1) | MXPA02000033A (tr) |
| NO (1) | NO20016187D0 (tr) |
| NZ (1) | NZ515348A (tr) |
| OA (1) | OA11952A (tr) |
| PA (1) | PA8496701A1 (tr) |
| PE (1) | PE20010322A1 (tr) |
| PL (1) | PL352899A1 (tr) |
| SK (1) | SK18672001A3 (tr) |
| TN (1) | TNSN00137A1 (tr) |
| TR (1) | TR200103688T2 (tr) |
| UY (1) | UY26211A1 (tr) |
| WO (1) | WO2000078759A1 (tr) |
| ZA (1) | ZA200110387B (tr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387925B1 (en) * | 1999-06-01 | 2002-05-14 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
| US6939873B2 (en) | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| US6756379B2 (en) * | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| EP1551846A1 (en) * | 2002-10-04 | 2005-07-13 | Merck Sharp & Dohme Ltd. | Azabicyclic spiroether derivatives as receptor antagonists |
| PT1569627E (pt) | 2002-12-11 | 2009-01-20 | Taro Pharma Ind | Método de tratamento de doenças do movimento utilizando derivados do ácido barbitúrico |
| CA2572797A1 (en) * | 2004-07-02 | 2006-01-12 | Daniella Gutman | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
| EP2081576A4 (en) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| SK390692A3 (en) * | 1991-05-31 | 1998-02-04 | Pfizer | Quinuclidine derivatives, preparation method thereof and use |
| ATE147385T1 (de) * | 1992-11-12 | 1997-01-15 | Pfizer | Chinuclidin derivat als substanz p antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
-
2000
- 2000-05-04 US US09/564,528 patent/US6262067B1/en not_active Expired - Fee Related
- 2000-06-06 TR TR2001/03688T patent/TR200103688T2/tr unknown
- 2000-06-06 CN CN00809305A patent/CN1390216A/zh active Pending
- 2000-06-06 PL PL00352899A patent/PL352899A1/xx not_active Application Discontinuation
- 2000-06-06 AP APAP/P/2001/002367A patent/AP2001002367A0/en unknown
- 2000-06-06 EA EA200101179A patent/EA004264B1/ru not_active IP Right Cessation
- 2000-06-06 MX MXPA02000033A patent/MXPA02000033A/es unknown
- 2000-06-06 EP EP00929745A patent/EP1187834A1/en not_active Withdrawn
- 2000-06-06 EE EEP200100698A patent/EE200100698A/xx unknown
- 2000-06-06 PA PA20008496701A patent/PA8496701A1/es unknown
- 2000-06-06 JP JP2001504925A patent/JP2003502425A/ja active Pending
- 2000-06-06 NZ NZ515348A patent/NZ515348A/en unknown
- 2000-06-06 KR KR1020017016407A patent/KR20020030280A/ko not_active Application Discontinuation
- 2000-06-06 BR BR0011835-4A patent/BR0011835A/pt not_active IP Right Cessation
- 2000-06-06 AU AU47745/00A patent/AU767336B2/en not_active Ceased
- 2000-06-06 HU HU0201694A patent/HUP0201694A3/hu unknown
- 2000-06-06 SK SK1867-2001A patent/SK18672001A3/sk unknown
- 2000-06-06 CA CA002375265A patent/CA2375265A1/en not_active Abandoned
- 2000-06-06 OA OA1200100314A patent/OA11952A/en unknown
- 2000-06-06 CZ CZ20014458A patent/CZ20014458A3/cs unknown
- 2000-06-06 WO PCT/IB2000/000756 patent/WO2000078759A1/en not_active Application Discontinuation
- 2000-06-06 IL IL14641000A patent/IL146410A0/xx unknown
- 2000-06-13 CO CO00043885A patent/CO5190663A1/es not_active Application Discontinuation
- 2000-06-20 UY UY26211A patent/UY26211A1/es not_active Application Discontinuation
- 2000-06-20 AR ARP000103053A patent/AR024411A1/es not_active Application Discontinuation
- 2000-06-20 PE PE2000000613A patent/PE20010322A1/es not_active Application Discontinuation
- 2000-06-21 MA MA26007A patent/MA26744A1/fr unknown
- 2000-06-21 DZ DZ000113A patent/DZ3055A1/xx active
- 2000-06-21 TN TNTNSN00137A patent/TNSN00137A1/fr unknown
- 2000-06-22 EC EC2000003538A patent/ECSP003538A/es unknown
-
2001
- 2001-11-13 IS IS6161A patent/IS6161A/is unknown
- 2001-12-10 BG BG106205A patent/BG106205A/bg unknown
- 2001-12-11 HR HR20010920A patent/HRP20010920A2/hr not_active Application Discontinuation
- 2001-12-18 NO NO20016187A patent/NO20016187D0/no not_active Application Discontinuation
- 2001-12-19 ZA ZA200110387A patent/ZA200110387B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6751301A (en) | 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists | |
| PL356990A1 (en) | Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists | |
| HUP0202034A3 (en) | Heterocyclic substituted aminoazacycles useful as central nervous system agents | |
| HK1036623A1 (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists | |
| PL340282A1 (en) | Novel derivatives of cyclopentene useful as antagonists of motilin receptor | |
| IL142045A0 (en) | Naphthalenecarboxamides as tachykinin receptor antagonists | |
| IL146410A0 (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2] oct-3-yl)-(1so-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists | |
| PL330708A1 (en) | Derivatives of indolydine useful as antagonists of 5-ht-2c receptor | |
| PL350536A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor | |
| AU1296899A (en) | Phenyl-alkyl-imidazoles as h3 receptor antagonists | |
| IL145952A0 (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo [2.2.2.] oct-3-yl) - (5-iso-propyl-2-methoxybenzyl) - amine citrate as nk-1 receptor antagonists | |
| PL330796A1 (en) | Derivatives of indolin useful as antagonists of 5-ht-2c receptor | |
| AU1100300A (en) | Piperidyloxadiazoles as dopamine receptor antagonists | |
| AU1566499A (en) | Imidazol derivatives as muscarinic m3 receptor antagonists | |
| HUP0102710A2 (hu) | Új eljárás prosztaglandinvegyületek előállítására | |
| AU5966098A (en) | NK-1 receptor antagonists for the treatment of delayed emesis | |
| SI0912556T1 (en) | Indoline derivatives useful as 5-ht-2c receptor antagonists | |
| GB9814737D0 (en) | Fibrinogen receptor antagonists | |
| TW422077U (en) | Improved structure of chuck for mop | |
| AU2512800A (en) | Alpha1-adrenergic receptor antagonists |